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Abstract
Background: Cryptococcus neoformans is an encapsulated yeast and the most frequent cryptococcal species found
in humans. Cryptococcosis is considered an opportunistic infection as it affects mainly immunosuppressed
individuals. In humans, C. neoformans causes three types of infections: pulmonary cryptococcosis, cryptococcal
meningitis and wound or cutaneous cryptococcosis.
Case Presentation: An 81-year-old woman developed severe necrotizing cellulitis on her left arm without any
preceding injury. The patient had been treated with systemic corticosteroids over twenty years for rheumatoid
arthritis (RA). Skin biopsies of the wound area were initially interpreted as cutaneous vasculitis of unknown etiology.
However, periodic acid Schiff staining and smear analysis later revealed structures consistent with Cryptococcus
neoformans, and the infection was subsequently confirmed by culture. After the initiation of therapy with
fluconazole 400 mg per day the general condition and the skin ulcers improved rapidly and the patient was
discharged to a rehabilitation facility. Subsequently surgical debridement and skin grafting were performed.
Conclusions: Opportunistic infections such as cryptococcosis can clinically and histologically mimic cutaneous
vasculitis and have to be investigated rigorously as a differential diagnosis in immunosuppressed patients.
Background
Cryptococcus neoformans is an opportunistic encapsu-
lated yeast and the most frequent cryptococcal species
found in humans. Cryptococcus neoformans is composed
of three variants: C. neoformans var. gattii,v a r .grubii,
and var. neoformans. Cryptococcus neoformans var. gattii
is encountered mostly in tropical areas, but C. neofor-
mans var. gattii has been found recently responsible for
an ongoing outbreak of cryptococcosis in immunocom-
petent humans and animals on Vancouver Island,
Canada, and surrounding areas [1,2]. Cryptococcus neo-
formans var. gattii has now been shown to be different
enough from other subspecies for authors suggesting to
elevate it to its own species level [3,4].
Infections caused by C. neoformans var. gattii occur pre-
dominantly in apparently healthy hosts [5]. Cryptococcus
neoformans var. grubii and var. neoformans have a world-
wide distribution. Although, Cryptococcus neoformans
being isolated from decaying wood, fruits, vegetables, hay
and dust [6], bird droppings, especially of pigeons, are an
important source for cryptococcal infections [7]. Crypto-
coccosis is considered an opportunistic infection as it
affects mainly immunosuppressed individuals [5,8], for
instance of. HIV-infected patients [9], patients with pro-
longed glucocorticoid-treatment [10,11] after organ trans-
plantation [12,13] or patients with malignancies [14].
However, there are also some reports of cryptococcosis in
immunocompetent individuals [15,16]. Cryptococcosis is
believed to be acquired by inhalation of the infectious pro-
pagule from the environment. In humans, C. neoformans
causes three types of infections: pulmonary cryptococcosis,
cryptococcal meningitis and wound or cutaneous
cryptococcosis [17]. The skin lesions typically appear as
pedunculated, dome-shaped papules with an umbilicated
center. Approximately 15% of patients with systemic disse-
mination show secondary involvement of the skin [18].
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any medium, provided the original work is properly cited.Skin lesions are found in 5% of patients with cryptococcal
meningitis [19], and the frequency is higher in liver trans-
plant recipients receiving tacrolimus or in patients infected
with serotype D [20]. Primary cutaneous cryptococcosis
(PCC) without systemic infection has been perceived to be
a rare distinct clinical entity [18].
Here we report the case of a female elderly patient
suffering from rheumatoid arthritis, where a cryptococ-
cal cellulitis was initially clinically and histopathologi-
cally erroneously diagnosed as a cutaneous vasculitis.
Case presentation
An 81-year-old woman presented with skin ulceration,
swelling, erythema and severe pain of her left arm. The
skin lesions developed some months earlier and progressed
slowly. The patient reported no accidental injury and no
fever. The patient lived in a rural area, had no outdoor
hobbies and could not remember any insect bites at pre-
sentation. The initial lesion was only a point-shaped lesion.
In the course, the primary lesion enlarged and developed
into an ulcerous lesion. Concomitantly, the patient suffered
from rheumatoid arthritis (RA) and had been treated with
on average 20 mg prednisolone daily for over twenty years
by her primary care physician. She had never received any
disease modifying anti-rheumatic drug (DMARD) therapy.
She had no known allergies. She had not travelled for
many years and had no close contact to any animals.
On examination, the left fore and upper arm exhibited
several necrotic deep ulcerations, each approximately 6
cm in diameter. The lesions extended to the muscles
and tendons (Figure 1). Regional lymphadenopathy
involving the left axillary lymphnodes and cervical
lymphnodes were present. The right leg showed the
clinical signs of cellulitis. Inflammatory markers were
elevated (CRP 280 mg/l, leucocytes 16/nl) and the dif-
ferential blood count demonstrated an increased
percentage of neutrophils. Biopsies and aspirates from
several sites of the wound area and blood cultures were
obtained and laboratory analyses including immunologi-
cal parameters were performed. Intravenous piperacillin
3 × 4 g/d combined with sulbactam 3 × 1 g/d was
initiated as empirical treatment of bacterial cellulitis and
penicillin G 10 Mio. IE was added for presumed erysipe-
las of the right leg. A rapid improvement of the erysipe-
las was noted, but no change of the ulcerative cellulitis
of the left arm could be perceived. Three pairs of blood
cultures remained negative even after prolonged incuba-
tion for seven days. Rheumatoid factor (RF), anti-citrulli-
nated peptide antibodies (ACPA), anti-nuclear
antibodies (ANA), and anti-neutrophil cytoplasmic anti-
bodies (ANCA) were all tested negative. Chest x-ray and
abdominal ultrasound did not reveal any infectious
focus. Histological analysis of skin biopsies (haematoxy-
lin-eosin staining) displayed pyoderma. In addition iso-
lated pale spherical structures could be identified, that
were also detected by periodic acid-Schiff staining and
initially believed to be most likely exogenous contamina-
tions. A second biopsy showed signs of a cutaneous vas-
culitis consistent with cutaneous involvement of RA.
Due to the assumed rheumatoid vasculitis (RV), our col-
leagues from the Department of Dermatology initiated
an empirical treatment with systemic prednisolone.
However, there was neither response to the antibacterial
therapy nor to the systemic prednisolone in the clinical
course. Finally, four weeks after admission, investiga-
tions on a third skin biopsy including periodic acid-
Schiff (Figure 2) and Gomori’s methenamine silver stain
revealed C. neoformans. This finding was subsequently
verified by microbial culture. A wound aspirate from
the region of the left elbow was also positive for
C. neoformans.R e t r o s p e c t i v e l y ,o n ec o u l di d e n t i f y
C. neoformans as pale spherules in the first biopsy
Figure 1 Severe cellulitis on the forearm.
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the patient’s serum was once tested for cryptococcal
antigen with a negative result. A computed tomography
(CT) of the lung revealed a peripheral round solid lesion
approximately 1 cm in diameter of unknown etiology.
Sputum cultures could not be performed because the
patient had no cough. The radiologists judged the lung
lesion unlikely to represent a cryptococcoma, but the
written report did not specifically exclude this diagnosis
from the differential diagnosis. The lesion was too per-
ipheral for bronchoscopic guided biopsy and due to the
general condition of the patient an open lung biopsy
was not performed instead a follow-up CT scan in 3
month was recommended.
Figure 2 Cutaneous biopsy specimen. Periodic acid-Schiff staining with the presence of Cryptococcus neoformans (PAS-positive spherules with
prominent capsules in a zone of clearance or “halo” around the cells, original magnification × 630).
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Page 3 of 5Antimycotic therapy with intravenous fluconazole (400
mg daily) was initiated and the empirical intravenous
antibiotic therapy deescalated to ceftriaxone. The debris
at the base of the ulcera cleared rapidly and after 10 days
new formation of granulation tissue was noted on the
base of all skin ulcers. The antifungal treatment with
daily 400 mg fluconazole was continued orally for further
4 weeks. A follow-up CT scan of the lung after 6 weeks
d i dn o tr e v e a la n yc h a n g eo ft h ep u l m o n a r yl e s i o n .T h e
dose of prednisolone was slowly tapered without a flare
of the RA. Three month after the initial admittance and
after 6 weeks of rehabilitation, surgical debridement of
the necrotic area was performed, and the skin defect was
successfully closed with a mesh graft.
Discussion
As demonstrated by our case report, cutaneous cryptococ-
cal infection can mimic and therefore needs to thoroughly
differentiate from rheumatoid vasculitis, which also can
manifest with ulcerative skin lesions. Rheumatoid vasculi-
tis typically occurs in patients with long-standing, joint-
destructive RA. In one study, the mean duration between
the diagnosis of RA and the onset of vasculitis symptoms
was 13.6 years [21]. The classic skin lesions of rheumatoid
vasculitis are deep cutaneous ulcers on the lower extremi-
ties and must be distinguished from pyoderma gangreno-
sum, which is much less common in RA. In hindsight, the
diagnosis of rheumatoid vasculitis appeared unlikely in
our patient due to the absence of rheumatoid factor,
which is usually highly elevated in patients with RV
[22,23]. High titers of rheumatoid factor are reported con-
sistently to be the strongest predictor of the development
of rheumatoid vasculitis. Rheumatoid vasculitis in a
patient with seronegative RA is very rare manifestation
and only a paucity of such case reports have been pub-
lished to our knowledge [24,25].
Cryptococcus neoformans has been recognized to cause
systemic infection in immunocompromised patients for
a long time. However, the existence of primary cuta-
neous cryptococcosis a cryptococcal infection of the
skin without prior dissemination, as a distinct entity has
been discussed only during the last decades [18]. Neu-
ville et al. [18] have proposed criteria to distinguish pri-
mary and secondary cutaneous cryptococcosis. Criteria
for the diagnosis evidence of primary cutaneous crypto-
coccosis included the absence of signs of disseminated
infection and predominantly a solitary skin lesion on
unclothed areas of the skin presenting as a whitlow or
phlegmon. In addition, patients may present with regio-
nal lymphadenopathy. In our case, there was no solitary
skin lesion presenting as a withlow or phlegmon, and no
history of a skin injury, no participation in outdoor
activities and no exposure to bird droppings could be
inquired from the patient. On the basis of these data,
the disease of our patient should be classified as anato-
mically limited manifestations of a disseminated disease
state and therefore does not represent primary cuta-
neous cryptococcosis.
The current guidelines of the Infectious Diseases
Society of America (IDSA) recommend amphotericin B
based combination therapy with flucytocine as primary
induction therapy for all severe forms of disseminated
cryptococcal infections (cryptococcosis) followed by flu-
conazole consolidation therapy [26]. For patients with
limited pulmonary cryptococcosis and non-pumonary
cryptococcal infections in immunocompetent patients
without CNS-involvement initial therapywith flucona-
zole (400 mg per day) could be considered. Due to the
comorbidities and the age of our 81-year-old patient
and that there was no evidence for an involvement of
the central nervous system or internal organs other than
the potentially limited pulmonary involvement, we
refrained from administering the standard therapy of
amphotericin B and flucytosine for disseminated crypto-
coccosis [26]. Fortunately, we saw a rapid clinical
response to fluconazole in our patient.
Conclusions
In summary, this case report demonstrates that oppor-
tunistic infections, such as cutaneous cryptococcosis,
can clinically and histologically mimic cutaneous vascu-
litis. Rheumatoid vasculitis is exceptionally rare in
patients with absent rheumatoid factor. Therefore, cuta-
neous cryptococcosis and other opportunistic infections
have to be rigorously investigated as a differential diag-
nosis in patients with rheumatoid factor negative RA
with cutaneous lesions.
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